Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...
GlobalData on MSN17h
Lilly’s Phase III SERD breast cancer study has success in certain patients
The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...
The Pharma Letter18h
Lilly’s imlunestrant takes aim at oral SERD market
Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...
emjreviews.com15h
Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024
Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
healthandpharma10h
New Oral SERD Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
TD Cowen Keeps Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s ...
CDC says kids' flu shot rates have hit a record low
NBC News' Erika Edwards reports on the latest numbers from the Centers for Disease Control and how they compare to last ...